Pharma/biotech mergers and acquisitions during 2005

------------------------------------------------------------------------------- Company Partner Deal value($) Completed ------------------------------------------------------------------------------- Abraxis BioScience American BioScience $4.17billion TBC Accredo Health Inc. Pediatric Services of America Inc $72.3 million Oct 2005 Actavis Group hf Alpharma Inc $814.4 million Dec 2005 Actavis Group Keri Pharma Undisclosed Sep 2005 Actavis Group Higia AD Undisclosed Dec 2005 Actavis Group Amide Pharmaceutical $538.6 million TBC ALK-Abello AS Allerbio (AB) SA Undisclosed June 2005 Allergan Inc Inamed Corp $3.10 billion TBC Alliance Unichem Pharma DEP (75%) $14.6 million July 2005 Alliance Unichem Centro Europeo de Reparto Farmaceutico de Cataluna SA $26.4 million TBC Alliance Unichem Farmaceutica CentralSA$30.6 million TBC Altana GSK (Rx dermatology business) Undisclosed Sep 2005 AmeriSourceBergen Trent Drugs $83.2 million Oct 2005 American Antibiotics Consolidated Pharmaceuticals Undisclosed Aug 2005 Amgen Abgenix $2.20 billion TBC Antisoma Aptamera $20.3 million Feb 2005 Aptuit Infopro Solutions Inc Undisclosed TBC Aptuit Quintiles $126.6 million TBC AstraZeneca KuDOS Pharmaceuticals $210.0 million TBC Bausch & Lomb Shandong Chia Tai Freda Pharmaceutical (55% stake) $200.5 million TBC Biolab Sanus Farmaceutica Sintefina Industria e Comrrcio $10.0 million July 2005 BioScrip Inc Northland Medical Pharmacy Inc $12.2 million Oct 2005 Bionutrics Kirk Pharmaceuticals $11.9 million TBC Biovitrum AB Arexis AB Undisclosed Aug 2005 Biovitrum AB Cambridge Biotechnology Undisclosed April 2005 Boiron SA Dolisos(85% stake) $106.1 million TBC Celtic Pharma Development UK Xenova $11.4 million Sep 2005 Cephalon Cell Therapeutics $68.0 million TBC Cephalon Salmedix $164.8 million June 2005 Cephalon Zeneus Holdings $360.0 million Dec 2005 Corgentech AlgoRx Pharmaceuticals Undisclosed TBC Crucell NV Berna Biotech $458.2 million TBC Daiichi Pharmaceutical Co Daiichi Suntory Pharma Co (34% stake) $87.6 million TBC Dainippon Pharmaceutical Co Sumitomo Pharmaceuticals Co $2.12 billion Oct 2005 DSM Pharmaceuticals DSM Biologics Holding (40% stake) Undisclosed July 2005 DOR BioPharma Gastrotech Pharma AS $8.9 million NA Duramed Pharmaceuticals Inc FEI Women's Health $282.9 million TBC Dr Reddy's Labs Roche Holding AG's API business $59.6 million Q1 2006 (e) Emergent BioSolution Microscience Undisclosed TBC EntreMed Miikana Therapeutics $39.2 million TBC Evotec AG Evotec Neurosciences GmbH (78% stake) $44.9 million March 2005 Faes Farma SA Ipsen SA (Spanish general medicine subsidiary) $21.9 million Oct 2005 Ferrosan AS Nordic Sales Group AS (93% stake) Undisclosed TBC Galapagos NV BioFocus $33.1 million TBC Genextra SpA Tetys Srl (54% stake) Undisclosed July 2005 Genzyme Bone Care Int $558.7 million July 2005 GPC Biotech AG Axxima Pharma AG $16.5 million March 2005 GSK ID Biomedical Corp $1.29 billion Dec 2005 GSK Corixa $264.8 million Dec 2005 Innovata Quadrant Technologies $82.3 million July 2005 Inverness Medical Innovations Abbott Laboratories (Determine/ DainaScreen business) $54.6 million TBC Inverness Medical Innovations Inc Innogenetics Diagnostica y Terapeutica $18.7 million Sep 2005 Inyx Celltech Manufacturing Services $33.1 million Aug 2005 Inyx Aventis Pharmaceuticals (Puerto Rico) $13.7 million NA IVAX Corp Phoenix Scientific $253.9 million May 2005 Jubilant Organosys Target Research Associates Inc $33.5 million Oct 2005 Kos Pharmaceuticals Biovail Corp (US cardiovascular operations) $96.8 million May 2005 Johnson & Johnson Guidant $21.20 billion TBC Laboratoire Unither CreapharmSAS(50% stake)Undisclosed Nov 2005 Leiner Health Products Pharmaceutical Formulations (OTC solid dose drug unit) $23.3 million TBC Macrogenics Tolerance Therapeutics Undisclosed June 2005 Markiz Farma Skopinpharm ZAO (75% stake) $19.4 million May 2005 Mayne Pharma Srl PHT Pharma Srl Undisclosed June 2005 Mayne Group (Shareholders) Mayne Pharma Pty Undisclosed TBC Mayne Group (Shareholders) Mayne Group (pharmacy,consumer, imaging divisions) Undisclosed TBC Meda AB Viatris GmbH $914.9 million Sep 2005 MedImmune Cellective Therapeutics Undisclosed Oct 2005 Merck KGaA Survac ApS $13.2 million TBC Merck Genericos SL Prasfarma SA $23.8 million TBC Nektar Therapeutics Aerogen, $22.4 million TBC NeutraHealth BioCare $28.4 million TBC Nichi-iko Pharmaceutical Co Oriental Pharmaceutical Co (67% stake) Undisclosed TBC Nicholas Piramal India Avecia (Custom Drug Synthesis business) $16.7 million TBC Novartis AG Chiron Corp (56% stake not already owned) $5.78 billion TBC Novartis AG Eon Labs $6.81 billion Aug 2005 Novartis AG Hexal AG $5.28 billion June 2005 NPS BioTherapeutics Bayer AG (plasma products business) $544.4 million April 2005 Nycomed A/S Nycomed Holding A/S $2.27 billion May 2005 OAO Katren ZAO Katren (31% stake) $9.7 million TBC Orion Corporation (shareholders) Oriola-KD Corp Undisclosed TBC OPG Group NV Orfe SA (38% stake) $17.1 million TBC Ortho-McNeil Pharmaceutical Peninsula Pharmaceutical$226.9 million June 2005 OSI Pharmaceuticals Eyetech Pharmaceuticals $655.7 million Nov 2005 Paladin Labs Dimethaid Health Care $5.9 million Aug 2005 Pfizer Vicuron Pharmaceuticals $1.72 billion TBC Pfizer Idun Pharmaceuticals $264.9 million March 2005 Pfizer Angiosyn $496.6 million May 2005 Pharmaniaga Pegasus (Seychelles) Co Wuxi Worldbest Treeful Pharmaceutical Co (40% stake) $5.5 million TBC Pharmexa AS GemVax AS $11.8 million June 2005 Phoenix Pharmahandel AG Libra AD Undisclosed TBC PolyMedica Corp National Diabetic Pharmacies $30.9 million Aug 2003 Premier Research Gp PharmData $22.0 million July 2003 Priority Healthcare Corp SpectraCare (infusion pharmacy, management operations) Undisclosed June 2005 pSivida Control Delivery Systems Inc $104.0 million TBC QuatRx Pharmaceuticals Co Hormos Medical Oyj Undisclosed May 2005 Ranbaxy (Netherlands) BV Nihon Pharmaceutical Industry Co (40% stake) $92.2 million TBC Recordati SpA Merckle GmbH (branded drug business) $80.2 million Feb 2005 Roche GlycArt Biotechnology AG$183.2 million TBC Rottapharm SpA Biochimici PSN SpA $98.5 million TBC Salix Pharmaceuticals InKine Pharmaceutical $173.7 million TBC Sanitas AB Hoechst-Biotika spol sro$15.1 million May 2005 Sankyo Co Daiichi Pharmaceutical $7.70 billion March 2005 Schering Plough Corp NeoGenesis Pharma $16.9 million Feb 2005 Shire Pharmaceuticals Transkaryotic Therapies $1.18 billion July 2005 Sigma Arrow Pharmaceuticals $502.5 million Dec 2005 Solvay SA Fournier Pharma $1.45 billion July 2005 Solvay Pharma NeoPharma AB $86.2 million Jan 2005 Sosei Co Arakis $132.2 million Aug 2005 SR Pharma Atugen AG $10.9 million TBC Sun Pharma ICN Hungary Co Undisclosed Aug 2005 Takeda Syrrx $254.1 million NA Teva IVAX Corp $7.40 billion Jan 2006 (e) TopoTarget AS G2M Cancer Drugs AG $10.6 million Feb 2005 Triax Holdings Spear Pharmaceuticals Undisclosed July 2005 Xanodyne Pharma Aaipharma, $195.9 million July 2005 Zentiva NV Venoma Holdings $98.5 million Oct 2005 -------------------------------------------------------------------------------